Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (11932)	6/6/2004 11:13:43 AM
From: scaram(o)uche	Respond to of 52153

>> but will try my best << Hey, no skin off our butt if you don't choose a given session. While that session is of extreme interest, from an investment stand I'd be off popping small molecule presentations. :-) Kosan has (what could be) a teaser out re. the Haluska (Paul, not Frank) presentation tomorrow with 17AAG. Have fun. Don't forget a feather boa.

To: zeta1961 who wrote (11932)	6/6/2004 12:11:02 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Thanks Zeta - we much appreciate the "on-the-spot" reporting. That Erbitux/radiation study does look extremely complex for a P3 - seems to me they should have done the multiple arms in a P2 and then picked the best for a P3. When you have multiple arms like that the statistics becomes much harder and the power drops. Interesting that Erbitux seems to have had some success now in head and neck - that's what they started out doing before the colon cancer took front stage. Peter